Markets:

Overview

News

Currencies

International

Treasuries

AbbVie (NY:ABBV)

231.50 +4.00 (+1.76%)

Official Closing Price Updated: 7:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about AbbVie

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

86 87 Next >

Elliott Wave Technical Analysis: AbbVie Inc. ↗

August 07, 2024

An in-depth look at ABBV's price movements using the Elliott Wave Theory, helping traders identify potential opportunities based on current trends and market structure.

Via Talk Markets

AbbVie, Leidos, KKR And More On CNBC's 'Final Trades' ↗

August 06, 2024

Via Benzinga

Large Cap Biopharma And Healthcare, A Port In A Storm ↗

August 05, 2024

Healthcare and biopharma show nice gains in a volatile week.

Via Talk Markets

Worried About a Market Correction? 2 High-Yield Dividend Stocks You Can Buy Now and Hold Forever. ↗

August 05, 2024

Recent market pressure could worsen, but that won't stop these successful businesses from raising their dividend payouts.

Via The Motley Fool

Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years ↗

August 02, 2024

Via Benzinga

8 Health Care Stocks With Whale Alerts In Today's Session ↗

August 01, 2024

Via Benzinga

A Closer Look at AbbVie's Options Market Dynamics ↗

July 31, 2024

Via Benzinga

Evolus, A Medical Aesthetics Player, Becomes Profitable — Two Quarters Early ↗

July 31, 2024

The company reported $1.1 million in adjusted operating income, well ahead of expectations for a $2.6 million loss.

Via Investor's Business Daily

Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making? ↗

July 31, 2024

Kazia Therapeutics stock soared after positive clinical trials, which raises its profile amongst pharmas looking to buy promising candidates.

Via InvestorPlace

7 Stocks Set for a Major Bull Run ↗

July 31, 2024

Explore top stocks to buy, leading in social media, semiconductors, entertainment, restaurants, payments and biotechnology.

Via InvestorPlace

3 Powerhouse Growth Stocks to Load Up On During This Bull Market Cycle ↗

July 31, 2024

Here are three powerhouse growth stocks long-term investors may want to hone in on during this part of the market cycle.

Via InvestorPlace

Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations ↗

July 30, 2024

Top pharmaceutical companies including Bristol Myers, Johnson & Johnson, AbbVie, and AstraZeneca foresee limited impact from the 2026 Medicare drug price cuts, easing initial industry concerns.

Via Benzinga

3 High-Yield Dividend Stocks That Are Looking Super Hot ↗

July 29, 2024

Discover high-yield dividend stocks offering solid returns. Learn about AbbVie, Target, and Abbott for reliable income and growth potential.

Via InvestorPlace

3 Dividend-Paying ETFs to Secure Your Passive Income Stream ↗

July 29, 2024

Passive income and ETFs represent two compelling market concepts. Why not bring the two together with dividend-paying ETFs?

Via InvestorPlace

Topics ETFs

AbbVie Wins Analyst Confidence with Q2 Beat, Diverse Portfolio Fuels Long-Term Growth Expectations ↗

July 26, 2024

AbbVie reports Q2 earnings with adjusted EPS of $2.65, surpassing expectations. Net revenues hit $14.46 billion, reflecting a 4.3% increase. Analysts maintain a positive outlook with increased price...

Via Benzinga

Lockheed Martin To Rally Over 14%? Here Are 10 Top Analyst Forecasts For Friday ↗

July 26, 2024

Via Benzinga

Why AbbVie Stock Was Cruising Higher on Thursday ↗

July 25, 2024

The market was impressed with a notable increase in full-year guidance.

Via The Motley Fool

AbbVie (ABBV) Q2 2024 Earnings Call Transcript ↗

July 25, 2024

ABBV earnings call for the period ending June 30, 2024.

Via The Motley Fool

Topics Earnings

Stocks Rebound As US Economy Flexes Muscles, Small Caps Rally, Gold Falls: What's Driving Markets Thursday? ↗

July 25, 2024

Wall Street strongly rebounded Thursday after Wednesday’s slump, driven by stronger-than-expected economic growth in the last quarter, countering concerns of a slowdown.

Via Benzinga

Topics Economy

ABBV Stock Earnings: AbbVie Beats EPS, Beats Revenue for Q2 2024 ↗

July 25, 2024

ABBV stock results show that AbbVie beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

AbbVie Stock News: Why ABBV Is the Top Trending Ticker Today ↗

July 25, 2024

AbbVie stock is the top trending ticker on Yahoo Finance Thursday earnings news has ABBV investors pumped up this morning.

Via InvestorPlace

AbbVie's Q2 Earnings Beat Estimates, Raises Annual Profit On Strong Sales From Newer Immunology And Cancer Drugs ↗

July 25, 2024

AbbVie Inc. reported Q2 adjusted EPS of $2.65, beating the $2.57 consensus, with net revenues at $14.46 billion. Immunology sales rose to $6.97 billion, while Humira declined 29.8%. Oncology and...

Via Benzinga

Topics Earnings

AbbVie Slides Despite Beating Second-Quarter Views, Raising Guidance ↗

July 25, 2024

The company's biggest drug, Humira, is about to give way to Skyrizi when it comes to sales power.

Via Investor's Business Daily

Is AbbVie the Best Dividend Stock for You? ↗

July 25, 2024

The drug company has a famously strong dividend record -- and that looks set to continue.

Via The Motley Fool

7 Trustworthy Dividend Stocks to Steadily Build Your Portfolio ↗

July 24, 2024

With political rumblings poised to make things exciting, investors may turn to the stability of trustworthy dividend stocks.

Via InvestorPlace

Nasdaq, S&P Futures Slide On More Negative Tech Tidings As Focus Shifts To Q2 GDP Data: Strategist Says Trump Trades May Not Work Even If Ex-President Retakes White House ↗

July 25, 2024

Sentiment continues to be jittery, with the major index futures priming for a lower opening on Thursday as traders look ahead to the first read of second-quarter GDP data and more earnings. The tech...

Via Benzinga

Topics Government Stocks

AbbVie Earnings Preview: Will Humira's Expiry, New CEO Fuel A Bullish Surge? ↗

July 24, 2024

AbbVie will report Q2 earnings on Thursday. Investors watch for Humira impact and signs of recovery under new CEO.

Via Benzinga

AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now? ↗

July 22, 2024

The big pharma company's top drug is losing ground, but its dividend keeps rising.

Via The Motley Fool

Tesla, Alphabet, GM, Ford Lead Earnings Parade This Week As Market Struggles To Sustain The Summer Rally ↗

July 21, 2024

The earnings parade continues this week with a slightly accelerated tempo as analysts brace for a healthy reporting season.

Via Benzinga

10 Best Dividend Growth Stocks to Buy and Hold Forever ↗

July 21, 2024

Discover 10 dividend growth powerhouses that could turbocharge your portfolio's long-term performance.

Via The Motley Fool

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

86 87 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

AbbVie (NY:ABBV)

Headline News about AbbVie

Starting at $3.75/week.

Subscribe Today